Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Sepsis 1Infections 1Hematologic Neoplasms 1

Interventions

telavancin 1soybean oil, phospholipid emulsion 1drotrecogin alfa activated 1Trimethoprim, Sulfamethoxazole Drug Combination 1Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization 1Simvastatin 1Saline Solution 1Povidone-Iodine 1Methods 1Meropenem 1Massage 1Levofloxacin 1Hydrochloric Acid 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gentamicins 1Colistin 1Colchicine 1ClinOleic 1Anti-Bacterial Agents 1Amoxicillin-Potassium Clavulanate Combination 1Alkaline Phosphatase 1Acupuncture Therapy 12-Propanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Sepsis × drotrecogin alfa activated × Clear all
NCT00067730 2007-12-07

A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation

Eli Lilly and Company

Phase 4 Completed
7 enrolled
Other hematologic neoplasm

Infections, Sepsis, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡